Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.59 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.59 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.59 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.59 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.59 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.59 |
| ▸ | FABP2 | P12104 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13172090 | 0.89 | AKR1C3 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL732665 | 0.86 | AKR1C3 (0.55) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL1533399 | 0.83 | AKR1C3 (0.67) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL1002973 | 0.83 | AKR1C3 (0.50) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL3052655 | 0.81 | HDAC1 (0.44) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL24875457 | 0.81 | MT-CO2 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL30192791 | 0.81 | MT-CO2 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL8476208 | 0.81 | MT-CO2 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL4129677 | 0.80 | AKR1C3 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL11248505 | 0.80 | AKR1C3 (0.61) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225657-B | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-112225657-A | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2021-01-15 | — | — | CN | claimed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| CN-117957212-A | IL-17A modulators based on phenylacetamide and uses thereof | 戴斯阿尔法公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-112225657-B | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-112225657-A | Preparation method of flurbiprofen | 北京泰德制药股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| EP-0123629-B1 | PREPARATION OF BIARYL COMPOUNDS | ETHYL CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0100120-B1 | IMPROVEMENT IN THE PROCESS FOR PREPARING BIARYL COMPOUNDS VIA COUPLING OF AN ARYLAMINE WITH AN ARENE | Nobel Chemicals AB (SE) | 1988-02-03 | — | — | EP | disclosed |
| US-4721790-A | Nucleophilic substitution process for fluoronitroaralkyloxazoline | ETHYL CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
| EP-0135249-B1 | STYRENE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4557871-A | Novel styrene derivatives of the general formula | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1985-12-10 | — | — | US | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| US-4540795-A | Fluoronitroaralkyloxazolines, derivatives thereof, and nucleophilic substitution processes for preparing them | ETHYL CORPORATION (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0135249-A1 | Styrene derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | AKR1C3 3650/4885AKR1C2 3570/4885PTGS2 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.